Navigation Links
Leading Rehab Facility Urges Patients Not to Stop Taking Antidepressants After New Study Suggests Increased Risk of Heart Attacks and Strokes
Date:4/6/2011

MALIBU, Calif., April 6, 2011 /PRNewswire/ -- Cliffside Malibu, one of America's leading drug and alcohol treatment centers, is strongly urging its patients who are currently taking antidepressants not to stop, despite a new study and subsequent media reports that such drugs could raise the risk of heart attack or stroke in middle-age men taking the medications.  Cliffside is using e-mail, phone calls and face-to-face therapy sessions to encourage its patients who rely on those medications to continue doing so under close supervision by their psychiatrists.

"While the findings of this very preliminary study are interesting and should be taken seriously, we are strongly urging our patients to continue using antidepressants as prescribed," said Cliffside Malibu CEO Richard Taite.  "The immediate, serious risks to our patients were they to abruptly halt the use of antidepressants far outweigh potential adverse health effects."

A presentation at a cardiology conference earlier this week suggested antidepressants could lead to as much as a five percent increase in the thickness of the carotid artery.  The study's author, Dr. Amit Shah, has reportedly cautioned that the findings of the 513-person study are not enough to warrant taking patients off of antidepressants, and noted that depression elevates risk for heart disease.

"The symptoms of depression in our patients, many of whom suffer from mood and other disorders, are often acute and even life-threatening.  We are reaching out to every current and former patient to educate them and to ensure they make wise decisions in partnership with their physicians," added Taite.

About Cliffside Malibu

Cliffside Malibu is a full-service residential drug rehab and alcohol addiction treatment center in the Los Angeles area.  At Cliffside, highly trained experts administer individually tailored addiction rehabilitation programs for patients who place a premium on privacy, safety, and, most importantly, effectiveness.  The drug rehabilitation facility gets its name from its striking location, perched on a cliff overlooking the Pacific Ocean.  For more information, visit www.cliffsidemalibu.com or call 800-501-1988.  


'/>"/>
SOURCE Cliffside Malibu
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Leading Anti-Cancer Drugs: World Market Prospects 2011-2021
2. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
3. Newtech, Inc., a Leading Chinese EMS Patient Monitoring Company, Partners With Masimo to Incorporate rainbow® SET Noninvasive Measurement Capabilities Into New Patient Monitors
4. Leading Hospitals Committed to Healthcares Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management
5. Life Technologies Initiates Clinical Trials Leading to 510(k) Submission of a Class I and Class II HLA Sequence-Based Typing Solution
6. Quest Diagnostics to Acquire Celera, Strengthening Position as Worlds Leading Innovator in Molecular Diagnostics and Development
7. First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital
8. Two National Organizations Join DRIVE4COPD Movement to Raise Awareness of Nations Fourth Leading Cause of Death
9. PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry
10. DJO Global to Acquire Leading Therapeutic Footwear Provider, Dr. Comfort
11. Reportlinker Adds The 2011 Top Ten Worlds Leading Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):